Features include very common findings: Nervous system problems (abnormality of the nervous system); and common findings: Seizure, Cerebral calcification, Increased CSF protein concentration, and Somatic sensory dysfunction and others. 49 total HPO annotations.

Biomarker and diagnostic research for cysticercosis has been reported in the published literature.

No approved treatments are currently available for cysticercosis. An additional 2 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for cysticercosis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for cysticercosis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Phenotype severity distribution: 1 very common feature, 14 common features.

Estimated prevalence: Unknown (Unknown prevalence).

4 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE4, 1 PHASE2, 1 NA. Research is primarily sponsored by academic and government institutions.

268 publications have been identified in PubMed for cysticercosis. Kisho has analyzed 53 by research type. Research spans Review / Meta-Analysis (32%), Epidemiology / Natural History (26%), and Case Report / Case Series (21%).